<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009836</url>
  </required_header>
  <id_info>
    <org_study_id>2020-504-00CH4</org_study_id>
    <nct_id>NCT05009836</nct_id>
  </id_info>
  <brief_title>Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC</brief_title>
  <acronym>SANOVO</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+/MET+ NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase III Clinical Study on Savolitinib Combined with Osimertinib in Treatment of&#xD;
      EGFRm+/MET+ Locally Advanced or Metastatic Non-small Cell Lung Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy&#xD;
      and Safety of Savolitinib Combined with Osimertinib versus Placebo Combined with Osimertinib&#xD;
      as the First-line Therapy for Patients with EGFRm+/MET+ Locally Advanced or Metastatic&#xD;
      Non-small Cell Lung Cancer&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 31, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study plans to enroll 320 patients, and eligible patients will be randomized in a ratio of 1:1 into the following treatment groups using central randomization system (IWRS): • Study group: Savolitinib 600 mg or 400 mg QD orally + Osimertinib 80 mg QD orally&#xD;
• Control group: placebo 600 mg or 400 mg QD orally + Osimertinib 80 mg QD orally</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>17 months after the last patient enrolled</time_frame>
    <description>Progression-free survival (PFS) using Investigator assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>17 months after the last patient enrolled</time_frame>
    <description>Incidence and nature of treatment emergent adverse events (TEAE), the other safety variables including physical examination, vital signs and laboratory examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The objective response rate of the tumor (ORR)</measure>
    <time_frame>17 months after the last patient enrolled</time_frame>
    <description>the incidence of confirmed complete response or partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The disease control rate (DCR)</measure>
    <time_frame>17 months after the last patient enrolled</time_frame>
    <description>the incidence of complete response, partial response and stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>17 months after the last patient enrolled</time_frame>
    <description>the duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>17 months after the last patient enrolled</time_frame>
    <description>the time from the date of randomization to the date of death (all causes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>17 months after the last patient enrolled</time_frame>
    <description>the period from the date of randomization to the date when the criteria for complete response or partial response was first measured (first record shall prevail).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>17 months after the last patient enrolled</time_frame>
    <description>Progression-free survival (PFS) using IRC as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of diagnostic technology</measure>
    <time_frame>17 months after the last patient enrolled</time_frame>
    <description>The residual samples may be used for development of MET Companion Diagnostics (CDx)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Savolitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Savolitinib 600 mg or 400 mg QD orally +Osimertinib 80 mg QD orally ( every 3 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 600 mg or 400 mg QD orally+ Osimertinib 80 mg QD orally ( every 3 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Savolitinib</intervention_name>
    <description>Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.</description>
    <arm_group_label>Savolitinib</arm_group_label>
    <other_name>HMPL-504</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Fully aware of this study and voluntary to sign the informed consent form, and being&#xD;
             willing and able to comply with the study procedure;&#xD;
&#xD;
          2. Age ≥ 18&#xD;
&#xD;
          3. In accordance with the Eighth Edition of TNM Staging of Lung Cancer by the&#xD;
             International Association for the Study of Lung Cancer and American Joint Committee on&#xD;
             Cancer, and patients with histologically or cytologically confirmed unresectable&#xD;
             locally advanced (stage ⅢB/ⅢC), metastatic or recurrent (stage IV) NSCLC who are not&#xD;
             suitable for radical concurrent chemoradiotherapy;&#xD;
&#xD;
          4. Carrying two common EGFR mutations clearly related with the sensitivity to EGFR-TKI&#xD;
             (i.e., exon 19 deletion, and L858R) and c-MET overexpression&#xD;
&#xD;
          5. Having measurable lesions (in accordance with RECIST 1.1 criteria);&#xD;
&#xD;
          6. ECOG Performance Status score 0 or 1, or Karnofsky score ≥80;&#xD;
&#xD;
          7. Survival is expected to exceed 12 weeks;&#xD;
&#xD;
          8. No any previous systematic antitumor therapy for advanced/metastatic disease;&#xD;
&#xD;
          9. adequate bone marrow reserve or organ function&#xD;
&#xD;
         10. Female patients of childbearing potential must agree to use effective contraceptive&#xD;
             methods from screening period to 4 weeks after discontinuation of the study drug 11.&#xD;
             Male patients whose sexual partners are women of childbearing potential must use&#xD;
             condoms during sexual intercourse during the study and within 6 months after&#xD;
             discontinuation of study drug&#xD;
&#xD;
        12. Being able to take or swallow the drug orally.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with EGFR inhibitors or MET inhibitors;&#xD;
&#xD;
          2. Currently having other malignant tumors, or having other infiltrating malignant tumors&#xD;
             in the past 5 years&#xD;
&#xD;
          3. Antitumor therapy within 2 weeks prior to the start of study treatment, including&#xD;
             hormone therapy, biotherapy, immunotherapy or the traditional Chinese medicine for&#xD;
             antitumor indication;&#xD;
&#xD;
          4. Having received extensive radiotherapy (including radionuclide therapy, e.g., Sr-89)&#xD;
             within 4 weeks prior to the start of study treatment or palliative local radiotherapy&#xD;
             within one week prior to the start of study treatment, or the above adverse reactions&#xD;
             of radiotherapy did not recover;&#xD;
&#xD;
          5. Having received a major surgery within 4 weeks prior to the start of study treatment&#xD;
             or a minor surgery (except biopsy, and venous catheterization) within one week prior&#xD;
             to the start of study treatment;&#xD;
&#xD;
          6. Currently receiving the potent CYP3A4 inducers or potent CYP1A2 inhibitors within two&#xD;
             weeks prior to the start of study treatment;&#xD;
&#xD;
          7. Having not been sufficiently recovered from the toxicity and/or complication resulting&#xD;
             from any interventional measure prior to the start of treatment;&#xD;
&#xD;
          8. Clinically significant active infection, including but not limited to tuberculosis,&#xD;
             human immunodeficiency virus (HIV) infection (positive HIV1/2 antibody);&#xD;
&#xD;
          9. Active hepatitis B, or active hepatitis C;&#xD;
&#xD;
         10. Acute myocardial infarction, unstable angina pectoris, stroke or transient ischemic&#xD;
             attack;&#xD;
&#xD;
         11. Uncontrollable hypertension despite the use of drugs,&#xD;
&#xD;
         12. Mean resting corrected QT interval (QTcF) or Any important abnormality in rhythm;&#xD;
&#xD;
         13. Patients whose known cancerous thrombus or deep vein thrombosis are stable for ≥2&#xD;
             weeks after receiving treatment with low molecular weight heparin (LMWH) or analogues&#xD;
             with similar efficacy can be enrolled;&#xD;
&#xD;
         14. Any important abnormality in rhythm&#xD;
&#xD;
         15. Presence of meningeal metastasis, spinal cord compression or active brain metastasis&#xD;
             prior to the start of study treatment.&#xD;
&#xD;
         16. Known allergy to the active or inactive ingredient of Savolitinib or Osimertinib;&#xD;
&#xD;
         17. Lack of compliance with participation in this clinical study or inability to comply&#xD;
             with the limitations and requirements of the study, as judged by investigators;&#xD;
&#xD;
         18. Having participated in other drug clinical trials and received the study drug within 3&#xD;
             weeks prior to the start of study treatment; 19. Known allergy to the active or&#xD;
             inactive ingredient of Savolitinib or Osimertinib; 20. Previous history of&#xD;
             interstitial lung diseases, drug-induced interstitial lung diseases, radiation&#xD;
             pneumonitis requiring glucocorticoid therapy and any active interstitial lung&#xD;
             diseases; 21. Pregnant and lactating women; 22. Any other disease, metabolic&#xD;
             abnormality, physical examination abnormality or laboratory examination abnormality,&#xD;
             certain disease or state, based on which there is a reason to suspect that the subject&#xD;
             is not suitable for the study drug, or one condition that will affect intepretaton of&#xD;
             the study results or put the subject at high risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yilong Wu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Provincial People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lu Chen</last_name>
    <phone>+86 021 -20673000</phone>
    <phone_ext>5014</phone_ext>
    <email>Luc@hutch-med.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

